| Protein Name: | DNA topoisomerase 1 (P11387) |
|---|---|
| Gene Name: | TOP1 |
| Description: | |
| PDB ID: | 1A31 |
| Protein Family: | PF14370, PS00176 |
| Protein Category: | Enzyme |
This panel provides drug-protein interaction and their ADRs along with references
| Interacting Drugs | Toxicity | Mechanism | Reference |
|---|---|---|---|
| Amsacrine | Dna Degradation | Different response of HL-60 cells to camptothecin@ teniposide@ or amsacrine via stabilization of the cleavable DNA-topoisomerase complexes through the pathway of rapidly triggered DNA degradation in S phase [ ADR Type 3 ] | Camptothecin, teniposide, or 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells |
| Doxorubicin | Dna Degradation | Different response of HL-60 cells to camptothecin@ teniposide@ or amsacrine via stabilization of the cleavable DNA-topoisomerase complexes by cell arrest in G2 and S. [ ADR Type 3 ] | Camptothecin, teniposide, or 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells |
| Esmolol | Apoptosis | Rat thymocytes were treated in culture with prednisolone or the DNA topoisomerase I or II inhibitors@The appearance of apoptotic cells in cultures treated with pharmacological concentrations of these drugs@ observed as early as 3-6 hr after treatment@ coincided with the selective loss of G0 cells in these cultures [ ADR Type 1 ] | Apoptosis of rat thymocytes triggered by prednisolone, camptothecin, or teniposide is selective to G0 cells and is prevented by inhibitors of proteases |
| Esmolol | Dna Degradation | Different response of HL-60 cells to camptothecin@ teniposide@ or amsacrine via stabilization of the cleavable DNA-topoisomerase complexes through the pathway of rapidly triggered DNA degradation in S phase [ ADR Type 3 ] | Camptothecin, teniposide, or 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells |
| Mitoxantrone | Dna Degradation | Different response of HL-60 cells to camptothecin@ teniposide@ or amsacrine via stabilization of the cleavable DNA-topoisomerase complexes by cell arrest in G2 and S [ ADR Type 3 ] | Camptothecin, teniposide, or 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells |
| Prednisolone | Apoptosis | Rat thymocytes were treated in culture with prednisolone or the DNA topoisomerase I or II inhibitors@The appearance of apoptotic cells in cultures treated with pharmacological concentrations of these drugs@ observed as early as 3-6 hr after treatment@ coincided with the selective loss of G0 cells in these cultures [ ADR Type 1 ] | Apoptosis of rat thymocytes triggered by prednisolone, camptothecin, or teniposide is selective to G0 cells and is prevented by inhibitors of proteases |
| Teniposide | Apoptosis | Rat thymocytes were treated in culture with prednisolone or the DNA topoisomerase I or II inhibitors@The appearance of apoptotic cells in cultures treated with pharmacological concentrations of these drugs@ observed as early as 3-6 hr after treatment@ coincided with the selective loss of G0 cells in these cultures. [ ADR Type 1 ] | Apoptosis of rat thymocytes triggered by prednisolone, camptothecin, or teniposide is selective to G0 cells and is prevented by inhibitors of proteases |
| Teniposide | Dna Degradation | Different response of HL-60 cells to camptothecin@ teniposide@ or amsacrine via stabilization of the cleavable DNA-topoisomerase complexes through the pathway of rapidly triggered DNA degradation in S phase. [ ADR Type 3 ] | Camptothecin, teniposide, or 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells |
This panel provides information on drug category